259 related articles for article (PubMed ID: 26467901)
1. Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial.
Rice CM; Marks DI; Ben-Shlomo Y; Evangelou N; Morgan PS; Metcalfe C; Walsh P; Kane NM; Guttridge MG; Miflin G; Blackmore S; Sarkar P; Redondo J; Owen D; Cottrell DA; Wilkins A; Scolding NJ
Trials; 2015 Oct; 16():463. PubMed ID: 26467901
[TBL] [Abstract][Full Text] [Related]
2. Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).
Rice CM; Marks DI; Walsh P; Kane NM; Guttridge MG; Redondo J; Sarkar P; Owen D; Wilkins A; Scolding NJ
BMJ Open; 2015 Sep; 5(9):e009090. PubMed ID: 26363342
[TBL] [Abstract][Full Text] [Related]
3. Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis - A phase I extension study (SIAMMS II).
Rice CM; Sarkar P; Walsh P; Owen D; Bidgood C; Smith P; Kane NM; Asghar S; Marks DI; Scolding NJ
Mult Scler Relat Disord; 2022 May; 61():103782. PubMed ID: 35397289
[TBL] [Abstract][Full Text] [Related]
4. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.
Rice CM; Mallam EA; Whone AL; Walsh P; Brooks DJ; Kane N; Butler SR; Marks DI; Scolding NJ
Clin Pharmacol Ther; 2010 Jun; 87(6):679-85. PubMed ID: 20445531
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
9. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
11. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.
Connick P; Kolappan M; Patani R; Scott MA; Crawley C; He XL; Richardson K; Barber K; Webber DJ; Wheeler-Kingshott CA; Tozer DJ; Samson RS; Thomas DL; Du MQ; Luan SL; Michell AW; Altmann DR; Thompson AJ; Miller DH; Compston A; Chandran S
Trials; 2011 Mar; 12():62. PubMed ID: 21366911
[TBL] [Abstract][Full Text] [Related]
12. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
[TBL] [Abstract][Full Text] [Related]
14. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P; De Angelis F; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S; Chataway J;
BMJ Open; 2018 Aug; 8(8):e021944. PubMed ID: 30166303
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Cambron M; Mostert J; Haentjens P; D'Hooghe M; Nagels G; Willekens B; Heersema D; Debruyne J; Van Hecke W; Algoed L; De Klippel N; Fosselle E; Laureys G; Merckx H; Van Wijmeersch B; Vanopdenbosch L; Verhagen W; Hupperts R; Hengstman G; Michiels V; Van Merhaegen-Wieleman A; De Keyser J
Trials; 2014 Jan; 15():37. PubMed ID: 24460863
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
17. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
Trials; 2019 May; 20(1):263. PubMed ID: 31072380
[TBL] [Abstract][Full Text] [Related]
18. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
19. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
